{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:14:43Z","timestamp":1793222083112,"version":"4.5.0"},"reference-count":29,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T00:00:00Z","timestamp":1652572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>Primary aldosteronism (PA) is a common secondary cause of hypertension. Literature regarding PA in pregnancy has demonstrated poor outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Compare the management and outcomes of PA in pregnancy to both high and low-risk matched controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a case-control trial conducted in a network of metropolitan hospitals in Sydney, Australia. PA women (positive salt suppression test) with singleton pregnancies delivered after 20 weeks\u2019 gestation were matched to women with high- and low-risk pregnancies. Management outcomes included pre-eclampsia prophylaxis and antihypertensive medications required prenatally, antenatally, and postnatally. Maternal outcomes included incidence of pre-eclampsia, gestational diabetes, hypokalemia, mode of delivery, and length of stay postpartum. Neonatal outcomes included gestation, birthweight, intensive care unit admission, and length of stay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty-nine women with 60 pregnancies were included (20 PA, 20 high risk, and 20 low risk). The number of antihypertensive medications women with PA took prepregnancy was similar to the high-risk group. A similar proportion of women in the PA and high-risk groups were prescribed pre-eclampsia prophylaxis and developed pre-eclampsia. Even after adjustment for several factors, PA was not independently associated with pre-eclampsia development. Women with PA had higher antihypertensive requirements and a longer stay in hospital postpartum than the high-risk group (both P\u2005=\u2005.02). There was no difference in neonatal adverse outcomes. Four women took epleronone during pregnancy without any adverse effects noted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Women with PA required more antihypertensives and had a longer postpartum length of stay than matched high-risk women, but similar rates of pre-eclampsia. There was no difference in the rate of neonatal intensive care admissions or adverse outcomes for neonates.<\/jats:p><\/jats:sec>","DOI":"10.1210\/clinem\/dgac311","type":"journal-article","created":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T15:55:56Z","timestamp":1652630156000},"page":"e3152-e3158","source":"Crossref","is-referenced-by-count":8,"title":["Assessment and Management of Primary Aldosteronism in Pregnancy: A Case\u2013Control Study"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1273-1236","authenticated-orcid":false,"given":"Elizabeth","family":"Downie","sequence":"first","affiliation":[{"name":"Department of Renal Medicine, South Western Sydney Local Health District (SWSLHD) , New South Wales (NSW) , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2255-8369","authenticated-orcid":false,"given":"Renuka","family":"Shanmugalingam","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, South Western Sydney Local Health District (SWSLHD) , New South Wales (NSW) , Australia"},{"name":"School of Medicine, Western Sydney University, NSW , Australia"},{"name":"Women\u2019s Health Initiative Translational Unit (WHITU), Ingham Institute, SWSLHD , NSW , Australia"},{"name":"South Western Sydney Clinical School, University of New South Wales (UNSW) , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Hennessy","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, South Western Sydney Local Health District (SWSLHD) , New South Wales (NSW) , Australia"},{"name":"School of Medicine, Western Sydney University, NSW , Australia"},{"name":"Women\u2019s Health Initiative Translational Unit (WHITU), Ingham Institute, SWSLHD , NSW , Australia"},{"name":"South Western Sydney Clinical School, University of New South Wales (UNSW) , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Makris","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, South Western Sydney Local Health District (SWSLHD) , New South Wales (NSW) , Australia"},{"name":"School of Medicine, Western Sydney University, NSW , Australia"},{"name":"Women\u2019s Health Initiative Translational Unit (WHITU), Ingham Institute, SWSLHD , NSW , Australia"},{"name":"South Western Sydney Clinical School, University of New South Wales (UNSW) , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,5,15]]},"reference":[{"issue":"1","key":"2022071417242692000_CIT0001","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism. A cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med."},{"key":"2022071417242692000_CIT0002","doi-asserted-by":"crossref","first-page":"162804","DOI":"10.4061\/2011\/162804","article-title":"Changes in the perceived epidemiology of primary hyperaldosteronism","volume":"2011","author":"Fagugli","year":"2011","journal-title":"Int J Hypertens."},{"issue":"4","key":"2022071417242692000_CIT0003","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.bpobgyn.2011.01.006","article-title":"Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy","volume":"25","author":"Hutcheon","year":"2011","journal-title":"Best Pract Res Clin Obstet Gynaecol."},{"key":"2022071417242692000_CIT0004","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.ecl.2019.08.011","article-title":"Evaluation and management of endocrine hypertension during pregnancy","volume":"48","author":"Corsello","year":"2019","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"1","key":"2022071417242692000_CIT0005","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1530\/EJE-14-0444","article-title":"Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy","volume":"172","author":"Riester","year":"2015","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2022071417242692000_CIT0006","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.preghy.2015.08.003","article-title":"Primary aldosteronism and pregnancy","volume":"5","author":"Morton","year":"2015","journal-title":"Pregnancy Hypertens"},{"issue":"3","key":"2022071417242692000_CIT0007","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000507116","article-title":"Preeclampsia: a diagnosis-nondiagnosis that is too easily made: the case of primary hyperaldosteronism","volume":"45","author":"Piccoli","year":"2020","journal-title":"Kidney Blood Press Res."},{"key":"2022071417242692000_CIT0008","article-title":"Treatment of primary aldosteronism","volume-title":"UpToDate","author":"Young","year":"2020"},{"key":"2022071417242692000_CIT0009","author":"Australian medicines handbook"},{"issue":"4","key":"2022071417242692000_CIT0010","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1530\/acta.0.0950540","article-title":"Disturbances in sexual differentiation of rat foetuses following spironolactone treatment","volume":"95","author":"Hecker","year":"1980","journal-title":"Acts endocrinology."},{"issue":"1","key":"2022071417242692000_CIT0011","first-page":"A44","article-title":"Management dilemmas of Conn\u2019s syndrome in pregnancy","volume":"91","author":"Ford","year":"2013","journal-title":"Arch Dis Child Fetal Neonatal Ed."},{"issue":"1","key":"2022071417242692000_CIT0012","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ccr3.355","article-title":"Eplerenone use in primary aldosteronism during pregnancy","volume":"4","author":"Gunganah","year":"2015","journal-title":"Clin Case Rep"},{"issue":"2","key":"2022071417242692000_CIT0013","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000506287","article-title":"Primary aldosteronism and pregnancy","volume":"45","author":"Zelinka","year":"2020","journal-title":"Kidney Blood Press Res."},{"issue":"9","key":"2022071417242692000_CIT0014","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline","volume":"93","author":"Funder","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022071417242692000_CIT0015","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1161\/HYPERTENSIONAHA.119.14107","article-title":"Clinical influence of nonadherence with prophylactic aspirin in preventing preeclampsia in high-risk pregnancies","volume":"75","author":"Shanmugalingam","year":"2020","journal-title":"Hypertension."},{"issue":"5","key":"2022071417242692000_CIT0016","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/ajo.12399","article-title":"SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014","volume":"55","author":"Lowe","year":"2015","journal-title":"Aust N Z J Obstet Gynaecol."},{"key":"2022071417242692000_CIT0017","volume-title":"ADIPS consensus guidelines for the testing and diagnosis of hyperglycaemia in pregnancy in Australia and New Zealand","author":"Nankervis","year":"2014"},{"key":"2022071417242692000_CIT0018","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1651-2227.2006.tb02371.x","article-title":"Enrolment and baseline characteristics in the WHO Multicentre Growth Reference Study","volume":"450","author":"WHO Multicentre Growth Reference Study Group","year":"2006","journal-title":"Acta Paediatr Suppl"},{"issue":"59","key":"2022071417242692000_CIT0019","article-title":"A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants","volume":"13","author":"Fenton","year":"2013","journal-title":"BMC Pediatr."},{"issue":"4","key":"2022071417242692000_CIT0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/01.aoa.0000389628.18661.20","article-title":"Primary aldosteronism and pregnancy: a case report","volume":"30","author":"Lu","year":"2010","journal-title":"Obstet Anesth Dig."},{"issue":"1","key":"2022071417242692000_CIT0021","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-2002-20170","article-title":"Diagnosis and management of primary aldosteronism in pregnancy: case report and review of the literature","volume":"19","author":"Okawa","year":"2002","journal-title":"Am J Perinatol."},{"issue":"1","key":"2022071417242692000_CIT0022","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2169\/internalmedicine.38.36","article-title":"Primary aldosteronism with aldosterone-producing adrenal adenoma in a pregnant woman","volume":"38","author":"Fujiyama","year":"1999","journal-title":"Intern Med."},{"key":"2022071417242692000_CIT0023","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/joim.12831","article-title":"Diagnosis and treatment of primary aldosteronism: practical clinical perspectives","volume":"285","author":"Young","year":"2019","journal-title":"J Intern Med."},{"issue":"1","key":"2022071417242692000_CIT0024","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1258\/om.2012.120012","article-title":"An endocrine cause of acute post-partum hypertension","volume":"6","author":"Bretherton","year":"2013","journal-title":"Obstet Med"},{"issue":"8","key":"2022071417242692000_CIT0025","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1007\/s00125-011-2158-9","article-title":"Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets","volume":"54","author":"Luther","year":"2011","journal-title":"Diabetologia."},{"issue":"5","key":"2022071417242692000_CIT0026","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1161\/HYPERTENSIONAHA.119.13922","article-title":"Primary aldosteronism decreases insulin secretion and increases insulin clearance in humans","volume":"75","author":"Adler","year":"2020","journal-title":"Hypertension."},{"issue":"8","key":"2022071417242692000_CIT0027","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93136","article-title":"Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism","volume":"2","author":"Arlt","year":"2017","journal-title":"JCI Insight."},{"issue":"2","key":"2022071417242692000_CIT0028","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1210\/en.2002-220708","article-title":"The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related","volume":"144","author":"Rafestin-Oblin","year":"2003","journal-title":"Endocrinology"},{"issue":"2","key":"2022071417242692000_CIT0029","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/HYPERTENSIONAHA.111.187237","article-title":"Eplerenone use in primary aldosteronism during pregnancy","volume":"59","author":"Cabassi","year":"2012","journal-title":"Hypertension"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac311\/43971674\/dgac311.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/8\/e3152\/44886546\/dgac311.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/8\/e3152\/44886546\/dgac311.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T16:20:52Z","timestamp":1700583652000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/8\/e3152\/6586045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,15]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,5,15]]},"published-print":{"date-parts":[[2022,7,14]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac311","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,5,15]]}}}